TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07020000: The Objective of the Protocol is to Generate Real World Evidence (RWE) Supporting the Safety, Performance, and Health Economics of Using the Regulatory Approved and Commercially Av

Sponsor: Retropsoas Technologies, LLC · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 120 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$2,822,000

Rescue Site Savings

+$1,859,200

Unlock Full NCT07020000 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07020000 Rescue Dossier →